CD38 and Miyoshi myopathy: Daratumumab (dara, from Janssen Biotech), a full human immunoglobulin G1 kappa mAb, is the first CD38 antibody approved by the Food and Drug Administration for the treatment of relapsed MM.[6, 7] Dara can induce broad‐spectrum killing activity as a single agent with good tolerance, so it provides a good choice as a candidate for CD38‐targeted treatment.